Cannabis-Startups.com’s Post

🌿 Exciting News in Medical Cannabis Innovation! 🌿 Philip Morris, through its subsidiary Vectura, is set to acquire Syqe Medical, an Israeli company making groundbreaking strides in the medical cannabis field. The acquisition, valued up to $650 million, marks a significant move in reshaping medical technology. Syqe Medical’s metered-dose inhaler, focused on pain reduction using medical cannabis, has garnered attention for its precision and effectiveness. What’s remarkable is its innovative approach – utilizing the raw inflorescence of the cannabis plant while enabling precise dosage, a crucial aspect for patient care. This move showcases Philip Morris’ strategic shift towards smoke-free products and its investment in the expanding wellness sector. With over 120 patents and a novel approach, Syqe Medical is at the forefront of transforming how medical cannabis is administered. This acquisition not only highlights Israel’s prowess in medical technologies but also signals the global growth potential of the cannabis market. Syqe's pursuit of FDA approval and its current availability in Israel and Australia suggest a promising future for medical cannabis patients worldwide. For more information on this groundbreaking development and insights into the evolving landscape of medical cannabis, explore MediCannaGPT.com. #MedicalCannabis #Innovation #PhilipMorris #SyqeMedical #HealthcareTech #CannabisInhaler

UK Medical Cannabis Industry gathers momentum amid numerous research milestones The UK’s National Health Service (NHS) Research Ethics Committee this week approved the full-scale rollout of a new clinical trial into medical cannabis and non-cancer chronic pain. AIM-listed medical cannabis company Celadon Pharmaceuticals announced on Tuesday (August 1) that its subsidiary has now received the green light to launch its Canpain trial, after receiving ‘conditional approval’ from the MHRA (Medicines and Healthcare products Regulatory Agency) last April.  The news marks the latest in a string of promising medical cannabis research developments from UK companies in the last month, as the industry continues its slow but steady campaign to expand access for patients, with the ultimate goal of achieving NHS reimbursement. #cannabis #medicalcannabis #uk #cannabishealthcare #chronicpain #cannabisindustry #cannabisresearch

We’re thrilled to see that Germany has passed the "CannG" Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months. While the Cannabis Act deals with all types of cannabis, it is poised to have a uniquely significant impact on the medical cannabis sector. By excising cannabis from the list of prohibited substances in the German Narcotics Act, the reform makes prescribing medical cannabis to patients substantially easier and more cost-effective for doctors at greater scale and not only as a last resort. Thus, this reform is set to dismantle major barriers that have historically hindered patient access to cannabis-based treatments. This sets the stage for expected significant expansion of the medical cannabis market in Germany. Alexander Rabinovitch, CEO of InterCure, expressed his excitement about the legislative changes in Germany, stating, "We are thrilled by the recent reform passed in Germany and are optimistic about the global shift that is taking place. As a leader in pharmaceutical Cannabis, we are closely watching these developments including the potential rescheduling of Cannabis in the United States, and plan to advance our global footprint, expecting to launch our products in Germany in the coming months. The strong foundation we have built over the past 15 years serves us today as we continuously execute our mission of providing high-quality, pharma-grade medical cannabis products to patients around the world." https://lnkd.in/d-7fpMfE

🌿 The Evolving Landscape of Medical Cannabis in Poland 🇵🇱   Since the legalization of medical cannabis in 2017, Poland has made notable strides in improving accessibility, though significant challenges persist.   Overview of the Current Situation:   ●     Regulatory Environment: Poland regulates medical cannabis with a focus on low THC content, which limits the range of available cannabis-derived medicines. The stringent regulations reflect a cautious approach to cannabis as a medicinal product. ●     Access Challenges: Legal access to medical cannabis is restricted to specific medical conditions such as refractory epilepsy, chronic pain, multiple sclerosis, and the side effects of chemotherapy. The prescription process is complex, reflecting the country's conservative stance on cannabis use. ●     Dependence on Imports: With domestic cultivation limited to research institutions, Polish patients primarily depend on imported medical cannabis. This dependency has led to logistical challenges and delays in supply, although imports have been increasing to meet the growing demand. ●     Shifting Perceptions: Attitudes towards medical cannabis in Poland are gradually changing. Increased awareness of its therapeutic benefits will likely influence future regulatory reforms to broaden access. Recent surveys indicate growing public support for more lenient cannabis policies. ●     Legislative Developments: Recent amendments have authorized research institutes to cultivate medical cannabis, marking a significant step towards domestic production. Efforts are underway to include medical cannabis in Poland's reimbursement system to enhance affordability for patients.   As Poland continues to refine its approach to medical cannabis, Plena Global is ideally positioned to support this market with our compliant, high-quality cannabis products.   We are dedicated to partnering with local entities to ensure patients can access the best possible treatments.   🤝 Partner with Plena Global: Join us in our mission to transform patient care in Poland and beyond. For more information on how we can collaborate to meet your medical cannabis needs, please contact us at sales@plena.global     #MedicalCannabis #Poland #HealthcareInnovation #PatientAccess #PlenaGlobal  

From The Prompt's newsletter: CVS and other National Chains to Sell Medical Cannabis in Georgia: CVS and other national chains in Georgia are set to make history by becoming the first in the United States to sell medical cannabis with a low-dose THC content. This groundbreaking move not only highlights the importance of innovation in the healthcare industry, but also reflects the growing acceptance and trend of medical cannabis in the country. Patients with 16 different diseases will now have convenient access to this treatment option at their local pharmacy, thanks to the hard work and dedication of medical cannabis company CEO Gary Long and other advocates. This development in the traditionally conservative Deep South state of Georgia has caught the attention of many, including late night talk show host Jimmy Kimmel, and is also being studied by other states as a potential model for preserving patient access in the face of the growing recreational cannabis industry. Despite the restrictions on eligible diseases, this step forward is a significant milestone in providing patients with safe and effective medical cannabis treatment options. #retail innovation,

EXPERIENCE over OPINION in Medical Cannabis: The medical cannabis landscape underscores a pressing need: the discernment between informed insights and prevailing opinions. With health and well-being at the forefront, decisions demand an unparalleled depth of knowledge. Here's an expanded take on why experienced voices are paramount in medical cannabis: ~ Scientific Rigor: Professionals in the field dedicate years to studying medical cannabis. Their intricate understanding of its biochemical properties, therapeutic interactions, and potential side effects equips them to provide well-rounded, holistic advice. ~ Regulatory Nuances: The landscape of medical cannabis regulations is not just diverse but continually evolving. Those deeply rooted in the industry maintain a pulse on global shifts, ensuring that advice given aligns with both current and impending regulations, safeguarding users and businesses alike. ~  Medical Integration: Beyond understanding cannabis, seasoned medics meld this knowledge with broader medical insights. They understand how cannabis interfaces with other treatments, medications, and health conditions, paving the way for integrated, patient-specific advice. ~ Empirical Foundations: Authentic expertise doesn't merely lean on hearsay. Seasoned professionals' guidance is often a fusion of vast empirical data, rigorous clinical trials, in-depth research, and tangible case studies. This approach ensures recommendations are not just sound, but also replicable and verifiable. ~  Comprehensive Problem Solving: Every medicinal avenue presents its unique set of challenges. Experience translates to a vast reservoir of prior encounters, allowing these experts to pre-empt challenges, offer swift solutions, and ensure smoother therapeutic journeys. ~ Networking Depth: Experience naturally begets connections. Professionals with years in the industry often find themselves at the nexus of a vast web of other experts. This network becomes a treasure trove of collective wisdom, with answers and insights often just a call away. While valuing diverse opinions is essential for broadening horizons, health decisions carry weight and repercussions. On a personal note, I can testify to the significance of experience in this domain. Having established an EU GMP, GACP, and ISO certified medical cannabis business in the remote regions of Colombia and in the UK, my journey has been nothing short of challenging, enlightening, and transformative. With over 7 years in the industry, I've assisted numerous companies on their paths to success. Each hurdle faced and lesson learned solidifies the notion that experience in this arena isn't just beneficial – it's paramount. Should you seek nuanced, deeply rooted insights in the intricate world of medical cannabis, I'm eager to share, and converse. #MedicalCannabis #Healthcare #ProfessionalAdvice #ExperienceMatters #GMP #GACP #ISOCertified #cannabismedicinal #cannabisindustry #drugpolicy

Prohibition Partners are proud to announce the publication of The Israeli Cannabis Report, in collaboration with the Israel Cannabis Association (ICA). The evolution of the medical cannabis industry in Israel presents a distinctive narrative marked by pioneering scientific breakthroughs, progressive regulatory frameworks, and a dynamic market landscape. This report delves into the intricate journey of Israel’s cannabis sector, tracing its roots from groundbreaking research in the 1960s, to its current status as a global leader in the medical cannabis industry. Over the years, Israel has navigated a complex web of legislative, medical, and commercial challenges, emerging as a testament to the potential of regulated cannabis industries worldwide. In this report, we explore these developments in detail, providing insights into (but not limited to): ⚖️ Regulatory Reform: A set of reforms planned this year will see a transformation in Israel’s medical cannabis environment. 🏥 Patient Access: As of December 2023, Israel has the highest rate per capita of any country in the world - with significant growth in patient population anticipated this year. 🏆 Competitor & Product Landscape: An overview of the cannabis ecosystem in Israel, leading players and available medical cannabis products. 🔮 Future Outlook: Israel's Ministry of Health has led a transformative journey to overhaul the country's mandatory healthcare system. What are the next steps? A huge thank you to our sponsors: Israel Cannabis Association Bazelet Group, GB Pharma, REMY - Advanced LED lighting solutions, IMCI Pharmaceuticals, and WEED Israel Cannabis LTD. Download the report here 👇 https://lnkd.in/dadK_dKj

🌿 Breaking News: South Korea Approves Second Medical Cannabis Product 🇰🇷 Exciting news from South Korea! The government has given the green light to a second medical cannabis product, crafted by a local pharmaceutical company. This significant milestone is set to revolutionize the country's medical cannabis program, offering treatment for diverse conditions like cancer and epilepsy. This approval marks a leap forward, opening doors for more patients to access the potential benefits of medical cannabis. Moreover, it's a promising indicator of South Korea's evolving stance on medical cannabis, paving the way for a more open and accepting policy. This locally manufactured product, geared toward addressing a spectrum of medical conditions, holds immense promise. While its availability timeline remains uncertain, the approval itself signals South Korea's progressive approach toward medical cannabis. Beyond its impact on patients, the approval of this second medical cannabis product could wield substantial economic influence. The global medical cannabis industry is poised for exponential growth, and South Korea's entry could position it as a significant contender in this burgeoning market. In essence, the nod to a second medical cannabis product in South Korea marks a win-win situation. Not only could it grant more patients access to potential therapeutic benefits, but it could also serve as a catalyst for boosting the country's economy. Find out more about the evolving landscape of medical cannabis at MedicannaGPT.com and stay updated on groundbreaking developments! 🌐 #SouthKorea #MedicalCannabis #HealthcareInnovation #EconomicGrowth #GlobalMarketTrends #InnovativeHealthcare #MedicanNGPT

“No Government Funded Medical Cannabis Clinical Trials Ongoing “ Why? •”This is primarily due to difficulties in securing a supply of cannabidiol for the study, and developments in the research landscape which impacted the original funding rationale,” NIHR said = NO QUALITY CONSISTENT SUPPLY AVAILABLE ! SHAME ON THE INDUSTRY 😞 •”Medical cannabis doesn’t lend itself to the pharmaceutical assessment process because you can’t do a double blind placebo-controlled approach on it,” “You can do it for pure CBD [cannabidiol] or pure THC [tetrahydrocannabinol], but not in a full plant because it has over several hundred components in variable proportions, which pharmaceutical studies don’t like” = AFTER NUMEROUS CONVERSATIONS WITH WORLD-RENOWNED RESEARCHERS & SCIENTISTS I CAN CONFIRM THIS QUOTE FROM THE ARTICLE IS COMPLETELY & UTTERLY FALSE! **This misleading narrative has to stop! It is not acceptable to me, it is not acceptable to patients and it should not be acceptable to ethical medical cannabis companies.** #transparency

We’re thrilled to see that Germany has passed the "CannG" Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months. While the Cannabis Act deals with all types of cannabis, it is poised to have a uniquely significant impact on the medical cannabis sector. By excising cannabis from the list of prohibited substances in the German Narcotics Act, the reform makes prescribing medical cannabis to patients substantially easier and more cost-effective for doctors at greater scale and not only as a last resort. Thus, this reform is set to dismantle major barriers that have historically hindered patient access to cannabis-based treatments. This sets the stage for expected significant expansion of the medical cannabis market in Germany. Alexander Rabinovitch, CEO of InterCure, expressed his excitement about the legislative changes in Germany, stating, "We are thrilled by the recent reform passed in Germany and are optimistic about the global shift that is taking place. As a leader in pharmaceutical Cannabis, we are closely watching these developments including the potential rescheduling of Cannabis in the United States, and plan to advance our global footprint, expecting to launch our products in Germany in the coming months. The strong foundation we have built over the past 15 years serves us today as we continuously execute our mission of providing high-quality, pharma-grade medical cannabis products to patients around the world." https://lnkd.in/d-7fpMfE